Metagenomi says $101.7m in the bank should last into 2028 as hemophilia A editor nears clinic
The gene-editing company's latest investor deck leads with its hemophilia A candidate and a cash balance it says covers operations for roughly the next two years.
Metagenomi Therapeutics has given investors a financial snapshot alongside an updated look at its pipeline, reporting $101.7 million in cash at the close of the third quarter of 2026. The company says that sum should cover its operating needs into 2028.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Metagenomi Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.